<p>Lexaria Bioscience Corp.（纳斯达克代码：LEXX，LEXXW）（以下简称 “公司” 或 “Lexaria”），作为全球药物递送平台的创新者，今天宣布完成其之前宣布的注册直接发行，按照纳斯达克规则以市场价格发行共计 2,661,600 股普通股，每股面值为 0.001 美元，购买价格为每股 1.315 美元。此外，在同时进行的私募中，公司发行了未注册的认股权证，允许购买最多 2,661,600 股普通股。认股权证的行使价格为每股 1.19 美元，立即可行使，并将在未注册认股权证的转售注册声明生效之日起五年内到期。</p>
<p>H.C. Wainwright &amp; Co. 担任此次发行的独家配售代理。</p>
<p>此次发行为公司带来的总毛收益约为 350 万美元，未扣除配售代理费用和公司需支付的其他发行费用。公司目前打算将此次发行的净收益用于推进其研发工作、资助营运资金及其他一般企业用途。</p>
<p>普通股（但不包括在私募中发行的认股权证或与这些认股权证相关的普通股）是根据证券交易委员会（“SEC”）于 2025 年 1 月 30 日宣布生效的 S-3 表格 “货架” 注册声明（文件编号：333-284407）进行发行的。普通股的注册直接发行仅通过招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与注册直接发行相关的招股说明书补充及招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。与注册直接发行相关的招股说明书补充及招股说明书的电子版也可通过联系 H.C. Wainwright &amp; Co., LLC，地址为纽约公园大道 430 号，3 楼，邮政编码 10022，电话（212）856-5711 或电子邮件 placements@hcwco.com 获取。</p>
<p>上述认股权证是在 1933 年证券法（“证券法”）第 4(a)(2) 条及其下的 D 条规章下的同时私募中发行的，并且与认股权证相关的普通股尚未根据证券法或适用的州证券法进行注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则这些认股权证及其相关的普通股不得在美国提供或出售。</p>
<p>本新闻稿不构成出售或招揽购买本文所述任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证之前，这种要约、招揽或销售是合法的。</p>
<p><strong>关于 Lexaria Bioscience Corp.及 DehydraTECH</strong></p>
<p>DehydraTECH™是 Lexaria 的专利药物递送配方和加工平台技术，改善了多种药物通过口服递送进入血液的方式。DehydraTECH 已多次证明能够提高生物吸收率，减少副作用，并更有效地穿越血脑屏障递送某些药物。Lexaria 运营着一个获得许可的内部研究实验室，并拥有强大的知识产权组合，已获得 56 项专利，另有多项专利正在全球申请中。欲了解更多信息，请访问 www.lexariabioscience.com。</p>
<p><strong>关于前瞻性声明的警示</strong></p>
<p>本新闻稿包含前瞻性声明。该术语在适用的证券法下有特定定义。这些声明可能通过诸如 “预期”、“如果”、“相信”、“计划”、“估计”、“期望”、“打算”、“可能”、“能够”、“应该”、“将会” 等类似表达来识别。本新闻稿中的前瞻性声明包括但不限于公司关于拟定用途的声明，涉及从发行中获得的收益，以及公司在开展研究计划、获得监管批准或补助，或从任何研究或研究中获得积极效果或结果的能力。这些前瞻性声明是基于当前信息反映公司最佳判断的估计，涉及多种风险和不确定性，无法保证公司实际实现这些前瞻性声明中披露的计划、意图或期望。因此，您不应对这些前瞻性声明过度依赖。可能导致实际结果与公司估计结果显著不同的因素包括但不限于市场和其他条件、政府监管和监管批准、管理和维持增长、负面宣传的影响、诉讼、竞争、科学发现、专利申请和批准过程、使用 DehydraTECH 技术的产品测试或使用可能产生的不利影响、公司维持现有合作关系并实现其利益的能力、与疫情相关或其他原因导致的计划研发的延迟或取消，以及公司在其公开公告和定期向美国证券交易委员会 EDGAR 提交的文件中不时可能识别的其他因素。公司仅为读者提供第三方网站的链接，且对第三方网站信息的全面性、准确性或及时性不承担任何责任。无法保证 Lexaria 所设想的专利及专利申请技术的任何用途、益处或优势将以任何方式或部分实现。本声明中的任何内容均未经过食品和药物管理局（FDA）的评估。与 Lexaria 相关的产品并不旨在诊断、治疗、治愈或预防任何疾病。本声明中包含的任何前瞻性声明仅在本声明日期有效，公司明确不承担更新本声明中任何前瞻性声明或链接到第三方网站的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的情况除外。</p>
<p><strong>投资者联系：</strong></p>
<p><strong>George Jurcic - 投资者关系负责人</strong></p>
<p>ir@lexariabioscience.com</p>
<p>电话：250-765-6424，分机 202</p>
<p><strong>来源：</strong> Lexaria Bioscience Corp.</p>
<p>查看 ACCESS Newswire 上的原始新闻稿</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExODMzOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExODMzOQ"/></p>

LEXX

<p>Lexaria Bioscience Corp. 宣布完成了一项 350 万美元的注册直接发行，按照纳斯达克规则以市场价格定价。此次发行包括 2,661,600 股普通股和相同数量的未注册认股权证。所得款项将用于研发、营运资金和一般企业用途。H.C. Wainwright & Co. 担任此次发行的承销商</p>

<p>Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the &#34;Company&#34; or &#34;Lexaria&#34;), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001 per share, at a purchase price of $1.315 per share. In addition, in a concurrent private placement, the Company issued unregistered warrants to purchase up to 2,661,600 shares of common stock. The warrants have an exercise price of $1.19 per share, are immediately exercisable and will expire five years from the date of the effectiveness of the resale registration statement registering the shares of common stock issuable upon exercise of the unregistered warrants.</p>
<div class="lb-trans"><p>Lexaria Bioscience Corp.（纳斯达克代码：LEXX，LEXXW）（以下简称 “公司” 或 “Lexaria”），作为全球药物递送平台的创新者，今天宣布完成其之前宣布的注册直接发行，按照纳斯达克规则以市场价格发行共计 2,661,600 股普通股，每股面值为 0.001 美元，购买价格为每股 1.315 美元。此外，在同时进行的私募中，公司发行了未注册的认股权证，允许购买最多 2,661,600 股普通股。认股权证的行使价格为每股 1.19 美元，立即可行使，并将在未注册认股权证的转售注册声明生效之日起五年内到期。</p>
</div><p>H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</p>
<div class="lb-trans"><p>H.C. Wainwright &amp; Co. 担任此次发行的独家配售代理。</p>
</div><p>The aggregate gross proceeds to the Company from the offering were approximately $3.5 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering to advance its research and development efforts, fund working capital and for other general corporate purposes.</p>
<div class="lb-trans"><p>此次发行为公司带来的总毛收益约为 350 万美元，未扣除配售代理费用和公司需支付的其他发行费用。公司目前打算将此次发行的净收益用于推进其研发工作、资助营运资金及其他一般企业用途。</p>
</div><p>The shares of common stock (but not the warrants issued in the private placement or the shares of common stock underlying such warrants) were offered by the Company pursuant to a &#34;shelf&#34; registration statement on Form S-3 (File No. 333-284407) that was declared effective by the Securities and Exchange Commission (the &#34;SEC&#34;) on January 30, 2025. The registered direct offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities being offered in the registered direct offering were filed with the SEC and are available at the SEC's website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (212) 856-5711 or e-mail at placements@hcwco.com.</p>
<div class="lb-trans"><p>普通股（但不包括在私募中发行的认股权证或与这些认股权证相关的普通股）是根据证券交易委员会（“SEC”）于 2025 年 1 月 30 日宣布生效的 S-3 表格 “货架” 注册声明（文件编号：333-284407）进行发行的。普通股的注册直接发行仅通过招股说明书进行，包括构成有效注册声明一部分的招股说明书补充。与注册直接发行相关的招股说明书补充及招股说明书已向 SEC 提交，并可在 SEC 网站 www.sec.gov 上获取。与注册直接发行相关的招股说明书补充及招股说明书的电子版也可通过联系 H.C. Wainwright &amp; Co., LLC，地址为纽约公园大道 430 号，3 楼，邮政编码 10022，电话（212）856-5711 或电子邮件 placements@hcwco.com 获取。</p>
</div><p>The warrants described above were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &#34;Securities Act&#34;), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.</p>
<div class="lb-trans"><p>上述认股权证是在 1933 年证券法（“证券法”）第 4(a)(2) 条及其下的 D 条规章下的同时私募中发行的，并且与认股权证相关的普通股尚未根据证券法或适用的州证券法进行注册。因此，除非根据有效的注册声明或适用的证券法注册要求的豁免，否则这些认股权证及其相关的普通股不得在美国提供或出售。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售或招揽购买本文所述任何证券的要约，也不应在任何州或司法管辖区进行这些证券的销售，除非在任何此类州或司法管辖区的证券法下进行注册或资格认证之前，这种要约、招揽或销售是合法的。</p>
</div><p><strong>About Lexaria Bioscience Corp. &amp; DehydraTECH</strong></p>
<div class="lb-trans"><p><strong>关于 Lexaria Bioscience Corp.及 DehydraTECH</strong></p>
</div><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 56 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.</p>
<div class="lb-trans"><p>DehydraTECH™是 Lexaria 的专利药物递送配方和加工平台技术，改善了多种药物通过口服递送进入血液的方式。DehydraTECH 已多次证明能够提高生物吸收率，减少副作用，并更有效地穿越血脑屏障递送某些药物。Lexaria 运营着一个获得许可的内部研究实验室，并拥有强大的知识产权组合，已获得 56 项专利，另有多项专利正在全球申请中。欲了解更多信息，请访问 www.lexariabioscience.com。</p>
</div><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示</strong></p>
</div><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as &#34;anticipate,&#34; &#34;if,&#34; &#34;believe,&#34; &#34;plan,&#34; &#34;estimate,&#34; &#34;expect,&#34; &#34;intend,&#34; &#34;may,&#34; &#34;could,&#34; &#34;should,&#34; &#34;will,&#34; and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&amp;D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p>
<div class="lb-trans"><p>本新闻稿包含前瞻性声明。该术语在适用的证券法下有特定定义。这些声明可能通过诸如 “预期”、“如果”、“相信”、“计划”、“估计”、“期望”、“打算”、“可能”、“能够”、“应该”、“将会” 等类似表达来识别。本新闻稿中的前瞻性声明包括但不限于公司关于拟定用途的声明，涉及从发行中获得的收益，以及公司在开展研究计划、获得监管批准或补助，或从任何研究或研究中获得积极效果或结果的能力。这些前瞻性声明是基于当前信息反映公司最佳判断的估计，涉及多种风险和不确定性，无法保证公司实际实现这些前瞻性声明中披露的计划、意图或期望。因此，您不应对这些前瞻性声明过度依赖。可能导致实际结果与公司估计结果显著不同的因素包括但不限于市场和其他条件、政府监管和监管批准、管理和维持增长、负面宣传的影响、诉讼、竞争、科学发现、专利申请和批准过程、使用 DehydraTECH 技术的产品测试或使用可能产生的不利影响、公司维持现有合作关系并实现其利益的能力、与疫情相关或其他原因导致的计划研发的延迟或取消，以及公司在其公开公告和定期向美国证券交易委员会 EDGAR 提交的文件中不时可能识别的其他因素。公司仅为读者提供第三方网站的链接，且对第三方网站信息的全面性、准确性或及时性不承担任何责任。无法保证 Lexaria 所设想的专利及专利申请技术的任何用途、益处或优势将以任何方式或部分实现。本声明中的任何内容均未经过食品和药物管理局（FDA）的评估。与 Lexaria 相关的产品并不旨在诊断、治疗、治愈或预防任何疾病。本声明中包含的任何前瞻性声明仅在本声明日期有效，公司明确不承担更新本声明中任何前瞻性声明或链接到第三方网站的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的情况除外。</p>
</div><p><strong>INVESTOR CONTACT:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p><strong>George Jurcic - Head of Investor Relations</strong></p>
<div class="lb-trans"><p><strong>George Jurcic - 投资者关系负责人</strong></p>
</div><p>ir@lexariabioscience.com</p>
<div class="lb-trans"><p>ir@lexariabioscience.com</p>
</div><p>Phone: 250-765-6424, ext 202</p>
<div class="lb-trans"><p>电话：250-765-6424，分机 202</p>
</div><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p>
<div class="lb-trans"><p><strong>来源：</strong> Lexaria Bioscience Corp.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新闻稿</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTExODMzOQ" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1118339"/></p>

Lexaria Bioscience Corp.宣布根据纳斯达克规则以市场价格完成 350 万美元的注册直接发行 | LEXX 股票新闻